WO2002004490A3 - Lipid metabolism molecules - Google Patents

Lipid metabolism molecules Download PDF

Info

Publication number
WO2002004490A3
WO2002004490A3 PCT/US2001/021432 US0121432W WO0204490A3 WO 2002004490 A3 WO2002004490 A3 WO 2002004490A3 US 0121432 W US0121432 W US 0121432W WO 0204490 A3 WO0204490 A3 WO 0204490A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipid metabolism
lmm
provides
metabolism molecules
molecules
Prior art date
Application number
PCT/US2001/021432
Other languages
French (fr)
Other versions
WO2002004490A2 (en
Inventor
Y Tom Tang
Yalda Azimzai
Debopriya Das
Michael Thornton
Dyung Aina M Lu
Catherine M Tribouley
Henry Yue
Ameena R Gandhi
Narinder K Walia
Farrah A Khan
Yan Lu
Monique G Yao
April J A Hafalia
Vicki S Elliott
Chandra Patterson
Preeti Lal
Jayalaxmi Ramkumar
Danniel B Nguyen
Mariah R Baugn
Original Assignee
Incyte Genomics Inc
Y Tom Tang
Yalda Azimzai
Debopriya Das
Michael Thornton
Dyung Aina M Lu
Catherine M Tribouley
Henry Yue
Ameena R Gandhi
Narinder K Walia
Farrah A Khan
Yan Lu
Monique G Yao
April J A Hafalia
Vicki S Elliott
Chandra Patterson
Preeti Lal
Jayalaxmi Ramkumar
Danniel B Nguyen
Mariah R Baugn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc, Y Tom Tang, Yalda Azimzai, Debopriya Das, Michael Thornton, Dyung Aina M Lu, Catherine M Tribouley, Henry Yue, Ameena R Gandhi, Narinder K Walia, Farrah A Khan, Yan Lu, Monique G Yao, April J A Hafalia, Vicki S Elliott, Chandra Patterson, Preeti Lal, Jayalaxmi Ramkumar, Danniel B Nguyen, Mariah R Baugn filed Critical Incyte Genomics Inc
Priority to JP2002509353A priority Critical patent/JP2004519207A/en
Priority to EP01952492A priority patent/EP1313857A2/en
Priority to CA002414219A priority patent/CA2414219A1/en
Priority to US10/332,426 priority patent/US20040029136A1/en
Priority to AU2001273235A priority patent/AU2001273235A1/en
Publication of WO2002004490A2 publication Critical patent/WO2002004490A2/en
Publication of WO2002004490A3 publication Critical patent/WO2002004490A3/en
Priority to US11/377,409 priority patent/US20070134680A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention provides human lipid metabolism molecules (LMM) and polynucleotides which identify and encode LMM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LMM.
PCT/US2001/021432 2000-07-07 2001-07-06 Lipid metabolism molecules WO2002004490A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002509353A JP2004519207A (en) 2000-07-07 2001-07-06 Lipid metabolism molecule
EP01952492A EP1313857A2 (en) 2000-07-07 2001-07-06 Lipid metabolism molecules
CA002414219A CA2414219A1 (en) 2000-07-07 2001-07-06 Lipid metabolism molecules
US10/332,426 US20040029136A1 (en) 2001-07-06 2001-07-06 Lipid metabolism molecules
AU2001273235A AU2001273235A1 (en) 2000-07-07 2001-07-06 Lipid metabolism molecules
US11/377,409 US20070134680A1 (en) 2000-07-07 2006-03-17 Lipid metabolism molecules

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US21680100P 2000-07-07 2000-07-07
US21680300P 2000-07-07 2000-07-07
US60/216,803 2000-07-07
US60/216,801 2000-07-07
US21823300P 2000-07-14 2000-07-14
US60/218,233 2000-07-14
US22004600P 2000-07-21 2000-07-21
US60/220,046 2000-07-21
US22073900P 2000-07-26 2000-07-26
US60/220,739 2000-07-26
US22282400P 2000-08-04 2000-08-04
US60/222,824 2000-08-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/377,409 Continuation US20070134680A1 (en) 2000-07-07 2006-03-17 Lipid metabolism molecules

Publications (2)

Publication Number Publication Date
WO2002004490A2 WO2002004490A2 (en) 2002-01-17
WO2002004490A3 true WO2002004490A3 (en) 2003-03-20

Family

ID=27559093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021432 WO2002004490A2 (en) 2000-07-07 2001-07-06 Lipid metabolism molecules

Country Status (5)

Country Link
EP (1) EP1313857A2 (en)
JP (1) JP2004519207A (en)
AU (1) AU2001273235A1 (en)
CA (1) CA2414219A1 (en)
WO (1) WO2002004490A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520031A (en) * 1999-11-12 2003-07-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 28 human secreted proteins
EP1329511A4 (en) 2000-09-19 2005-01-19 Kyowa Hakko Kogyo Kk Polypeptide having phospholipase a2 actiivty
WO2002031162A2 (en) * 2000-10-10 2002-04-18 Bayer Aktiengesellschaft Regulation of human phospholipase a2-like enzyme
WO2002038773A2 (en) 2000-11-08 2002-05-16 Millennium Pharmaceuticals, Inc. A human phospholipase c and uses thereof
JP4038181B2 (en) 2002-01-17 2008-01-23 田辺三菱製薬株式会社 Novel phospholipase A2 and its gene
JPWO2003076935A1 (en) * 2002-03-14 2005-07-07 協和醗酵工業株式会社 Preventive or therapeutic agent for dermatitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068871A2 (en) * 2000-03-13 2001-09-20 Lexicon Genetics Incorporated Human phospholipases and polynucleotides encoding the same
WO2001083771A2 (en) * 2000-04-29 2001-11-08 Merck Patent Gmbh Human phospholipase c delta 5

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068871A2 (en) * 2000-03-13 2001-09-20 Lexicon Genetics Incorporated Human phospholipases and polynucleotides encoding the same
WO2001083771A2 (en) * 2000-04-29 2001-11-08 Merck Patent Gmbh Human phospholipase c delta 5

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALVAREZ R A ET AL: "CDNA sequence and gene locus of the human retinal phosphoinositide-specific phospholipase C-beta-4 (PLCB4).", GENOMICS, vol. 29, no. 1, 1 September 1995 (1995-09-01), pages 53 - 61, XP001064391, ISSN: 0888-7543 *
DATABASE EMBL_HUM [online] 29 October 1999 (1999-10-29), HOU S ET AL: "The sequence of Homo sapiens BAC clone RP11-548H3", XP002211472, Database accession no. AC012510 *
LEE S B ET AL: "Molecular cloning,splice variants, expression, and purification of phospholipase C-delta4", JOURNAL OF BIOLOGICAL CHEMISTRY,, vol. 271, no. 1, 5 January 1996 (1996-01-05), pages 25 - 31, XP002180350, ISSN: 0021-9258 *
LIU N ET AL: "A new phospholipase C delta-4 is induced at S-phase of the cell cycle and appears in the nucleus.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 1, 1 May 1996 (1996-05-01), pages 355 - 360, XP002180351, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
CA2414219A1 (en) 2002-01-17
EP1313857A2 (en) 2003-05-28
JP2004519207A (en) 2004-07-02
AU2001273235A1 (en) 2002-01-21
WO2002004490A2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
WO2002046383A3 (en) Protein modification and maintenance molecules
WO2002063005A3 (en) Lipid-associated molecules
WO2002002603A3 (en) Protein modification and maintenance molecules
WO2001096546A3 (en) Protein phosphatases
WO2001032888A3 (en) Human transferase molecules
WO2002026950A3 (en) Transferases
WO2001053468A3 (en) Lipid metabolism enzymes and polynucleotides encoding them
WO2004044165A3 (en) Lipid-associated proteins
WO2004009797A3 (en) Protein modification and maintenance molecules
WO2004053068A3 (en) Protein modification and maintenance molecules
WO2003063688A3 (en) Protein modification and maintenance molecules
WO2002010363A3 (en) Protein phosphatases
WO2002060942A3 (en) Protein modification and maintenance molecules
WO2002004490A3 (en) Lipid metabolism molecules
WO2002024924A3 (en) Protein phosphatases
WO2001083524A3 (en) Rna metabolism proteins
WO2003031939A3 (en) Protein modification and maintenance molecules
WO2001064907A3 (en) Lipid metabolism enzymes
WO2002066646A3 (en) Neurotransmission-associated proteins
WO2001092527A3 (en) Regulators of apoptosis
WO2003100016A3 (en) Protein modification and maintenance molecules
WO2001085956A3 (en) Lipid metabolism enzymes
WO2003083084A3 (en) Protein modification and maintenance molecules
WO2002016597A3 (en) Lipid metabolism enzymes
WO2002031152A3 (en) Intracellular signaling molecules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2414219

Country of ref document: CA

Ref document number: 10332426

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001952492

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001952492

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001952492

Country of ref document: EP